Summary
This study will determine the pharmacodynamically-active dose of gevokizumab and the
tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in
patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic
renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC
anti-cancer therapy in subjects with mCRC and mGEC.